Clinical Trials on Anti-LGI1 Encephalitis

Total 774 results

Pfizer

Completed

Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

Tick-Borne Encephalitis

Japan
GlaxoSmithKline
Novartis Vaccines

Completed

Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Virus Diseases | Tick Borne Encephalitis

Czechia
Novartis Vaccines

Completed

An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE

Tick Borne Encephalitis (TBE)

Germany
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

Tick-Borne Encephalitis

United States
PATH

Completed

Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine

Japanese Encephalitis

Sri Lanka
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age (JECEVAX-2B)

Japanese Encephalitis

Vietnam
Boryung Pharmaceutical Co., Ltd

Completed

Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj (BR-JELITE)

Japanese Encephalitis

Korea, Republic of
Jiangsu Province Centers for Disease Control and...
Shandong Hengye Biotech Co., Ltd.

Completed

A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants

Encephalitis

China
Valneva Austria GmbH

Completed

Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country

Japanese Encephalitis

Philippines
Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
Valneva Austria GmbH

Completed

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Japanese Encephalitis
Valneva Austria GmbH

Completed

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Sanofi

Completed

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Japanese Encephalitis

Australia, United States
Sanofi

Completed

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Japanese Encephalitis | Encephalitis

United States, Australia
Sanofi

Completed

Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine

Japanese Encephalitis

Australia
Sanofi
PRA Health Sciences

Completed

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX

Japanese Encephalitis

United States
Helsinki University Central Hospital
Karolinska Institutet

Completed

Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis

Japanese Encephalitis
Indian Council of Medical Research

Unknown

Treatment of Japanese Encephalitis

Japanese Encephalitis

India
University of Liverpool

Completed

Flavivirus Cross-priming Potential of IMOJEV (FlaviPrime)

Japanese Encephalitis

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

Japanese Encephalitis

Vietnam
PATH
Mahidol University; Ministry of Health of Sri Lanka; Quintiles Singapore

Completed

Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age (JEV03)

Japanese Encephalitis

Sri Lanka
PATH

Completed

Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine

Japanese Encephalitis

Bangladesh
Sanofi Pasteur, a Sanofi Company

Completed

Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers

Japanese Encephalitis | Encephalitis

Thailand, Philippines
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Chulalongkorn University
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Japanese Encephalitis
Valneva Austria GmbH

Completed

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Boryung Pharmaceutical Co., Ltd
Samsung Medical Center; Seoul National University Hospital; Gachon University... and other collaborators

Completed

Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea

Japanese Encephalitis

Korea, Republic of
Sanofi

Completed

Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age

Japanese Encephalitis

India
Sanofi

Completed

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

Japanese Encephalitis | Encephalitis

Australia
Valneva Austria GmbH

Completed

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Japanese Encephalitis

Germany, Austria
University Medical Centre Ljubljana
University of Ljubljana School of Medicine, Slovenia

Completed

Tick-borne Encephalitis and Possible Borrelial Serology

Lyme Disease | Tick Borne Encephalitis

Slovenia
Novartis Vaccines

Completed

Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults

Tick Born Encephalitis

Czech Republic
Pfizer

Completed

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

Encephalitis, Tick-Borne

Poland
Novartis
Novartis Vaccines

Completed

Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children

Encephalitis, Tick-Borne

Germany
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years

Encephalitis, Tick-borne

Austria, Germany
Medical University of Vienna

Unknown

Application of a TBE-Vaccine in Obese Persons

Tick Borne Encephalitis

Austria
Ichor Medical Systems Incorporated
US Army Medical Research Institute of Infectious Diseases

Completed

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

Venezuelan Equine Encephalitis Virus Infection

United States
Pfizer

Completed

Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR

Encephalitis, Tick-borne

Poland
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

Encephalitis, Tick-borne

Germany
Liaoning Chengda Biotechnology CO., LTD

Recruiting

Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization

Japanese Encephalitis

China
Valneva Austria GmbH

Completed

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
U.S. Army Medical Research and Development Command

Unknown

Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine

Western Equine Encephalitis

United States
U.S. Army Medical Research and Development Command

Completed

Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine (EEE)

Eastern Equine Encephalitis

United States
Medical University of Vienna

Completed

Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine

Humoral and Cellular Immune Responses
DynPort Vaccine Company LLC, A GDIT Company

Withdrawn

Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine

Venezuelan Equine Encephalitis

United States

3

Subscribe